Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease
Patients with pulmonary arterial hypertension associated with congenital heart disease (CHD-PAH) after defect correction have a poor prognosis compared with other CHD-PAH patients. Therefore, it is important that these patients are treated as early and effectively as possible. Evidence supporting the use of PAH therapies in patients with corrected CHD-PAH from randomised controlled trials is limited. The purpose of these analyses was to characterise the corrected CHD-PAH patients from the GRIPHON study and examine the response to selexipag.
METHODS AND RESULTS:Out of the 110 patients diagnosed with corrected CHD-PAH, 55 had atrial septal defects, 38 had ventricular septal defects, 14 had persistent ducti arteriosus, and 3 had defects not further specified. Hazard ratios (HR) and 95% confidence intervals (CI) for the primary composite endpoint were calculated using Cox proportional hazard models. Compared with the non-CHD patients from GRIPHON, patients with corrected CHD-PAH were slightly younger, with a greater proportion being treatment-naive and in World Health Organization functional class I/II. The rate of the primary composite endpoint of morbidity/mortality was lower in patients with corrected CHD-PAH who were treated with selexipag compared with those treated with placebo (HR 0.58; 95% CI 0.25, 1.37). The most common adverse events were those known to be related to selexipag.
CONCLUSIONS:These post-hoc analyses of GRIPHON provide valuable information about a large population of patients with corrected CHD-PAH, and suggest that selexipag may delay disease progression and was well-tolerated in patients with corrected CHD-PAH.
Hunan Huateng Pharmaceutical Co., Ltd., founded in August 2013?, is a high-tech enterprise dedicated to the research and development and production of high-end biomedical chemical products, as well as the development of precision targeted anti-tumor drugs. The company develops and produces thousands of products, including monodisperse and polydisperse PEG derivatives, high-end biochemical reagents, pharmaceutical intermediates, APIs, preparations and targeted anti-tumor drugs.
Hunan Huateng Pharmaceutical Co., Ltd. has a research and development production base of 5,000 square meters in Changsha High-tech Zone, and another 37,000 square meters of APIs and preparation manufacturing plant under construction. After the completion of the production base, the company's annual production capacity of biomedical products will reach more than 5 billion yuan. The company's R&D center is equipped with high-end analytical instruments and high-end automatic reaction equipment, such as 400M NMR, Agilent LCMS, HPLC, GC, IR, GPC, automatic polarimeter, constant moisture titrator, low temperature reactor, high pressure hydrogenation reaction. We have our own R&D and logistics centers in China, the United States, Europe and many other countries. And we have set up an excellent and efficient R&D production and sales professional team to provide one-stop service for professional, personalized and technical support to all customers worldwide.
Huateng Pharmaceutical is committed to providing cost-effective pharmaceutical products and services to customers around the world with the belief of "Strive for the Human Health". Our goal is to build an internationally renowned new drug research and development platform, work together with high-end talents and all partners to make good medicine, cure diseases and make outstanding contributions to the development of human medicine and health!